9 Meters Biopharma, Inc.

Safety Score

Market Cap $1.36K
Debt $5.07M
Cash $7.62M
EV -$2.55M
FCF -$37.24M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$46.28M
EBIT	-$43.45M
ROA	-467%
FCF	-$37.24M
Equity	-$6.30M
Growth Stability	1
PE	-0
PB	-0
P/FCF	-0
Price/Cash	5.61K
Debt/Equity	-0.81
Debt/FCF	-0.14
Sales CAGR	-0%
Equity CAGR	23%
Earnings Growth YoY	22%
Earnings Growth QoQ	16%

Equity CAGR 5Y	68%
Equity CAGR 3Y	9%
Market Cap	$1.36K
Assets	$9.31M
Total Debt	$5.07M
Cash	$7.62M
Shares Outstanding	13.59M
EV	-2.55M
Safety Score	34%
Working Capital	-6.38M
Current Ratio	0.59
Shares Growth 3y	16%
Equity Growth QoQ	-362%
Equity Growth YoY	-120%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

9 Meters Biopharma Inc is a clinical-stage biopharmaceutical company focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. Its products include NM-002, Larazotide, NM-003 and others.

SEC Filings

Direct access to 9 Meters Biopharma, Inc. (NMTRQ) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2023
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2021
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does 9 Meters Biopharma, Inc. compare to its competitors?

Not enough data to generate a comparison chart between 9 Meters Biopharma, Inc. and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of 9 Meters Biopharma, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

9 Meters Biopharma, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for 9 Meters Biopharma, Inc..

Years

Calculation mode

= -$372M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$37M	-$37M	-$37M	-$37M	-$37M	-$37M	-$37M	-$37M	-$37M	-$37M	-$37M	-$372M
DCF		-$34M	-$31M	-$28M	-$25M	-$23M	-$21M	-$19M	-$17M	-$16M	-$14M	-$144M
Value	-$372M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	TTM
Net Margins	-106%	-153%	-468%	-	-	-	-	-	-
ROA	-	-92%	-1K%	282%	482%	-155%	-73%	-127%	-467%
ROE	-	-250%	447%	660%	281%	-191%	-88%	-2K%	-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	TTM
Debt over FCF	-	-	-	-0.34	-0.18	-0	-0	-0.53	-0.14
Debt over Equity	-0.62	0.02	-0.69	-1.42	-0.33	0	0	8.17	-0.81
Growth Stability	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-0.14)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (-0.81)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	CAGR 5Y
Revenue YoY growth	-	-51%	-54%	-	-	-	-	-	-
Earnings YoY growth	-	-29%	42%	174%	12%	127%	-40%	19%	-
Equity YoY growth	-	-144%	-179%	85%	163%	-434%	29%	-94%	68%
FCF YoY growth	-	-	-	276%	18%	8%	52%	26%	-